Cepheid Expands into New Markets with Innovative Solutions

Cepheid is expanding its reach into new markets with innovative solutions. The company has made significant strides in this area.

Cepheid's innovative solutions are based on its proprietary isothermal nucleic acid amplification technology. This technology allows for the rapid and accurate detection of nucleic acids.

By leveraging this technology, Cepheid is able to offer a wide range of diagnostic solutions for various markets. These solutions are designed to meet the unique needs of different industries and applications.

Cepheid's GeneXpert System was at the heart of the biohazard detection system for the United States Postal Service.

Launched in 2003, the program delivered over 15 million test results with no false positives. This achievement showcases the system's reliability and effectiveness.

The GeneXpert system was developed in collaboration with Northrop Grumman, highlighting the company's ability to partner with other organizations to tackle complex challenges.

The biothreat aspect of Cepheid's business grew significantly, but the company quickly returned to its core vision of delivering the GeneXpert system and diagnostic tests to the clinical market.

Cepheid entered the oncology market with the Xpert Breast Cancer STRAT4 test in 2017.

This marked a significant expansion of the company's product offerings.

The Xpert Breast Cancer STRAT4 test is a diagnostic and/or prognostic test for breast cancer.

Cepheid now offers tests for breast, prostate, and bladder cancer as well as leukemia.

The company's entry into the oncology market has allowed it to provide critical diagnostic and prognostic tools to healthcare professionals.

These tests can help doctors make more informed decisions about patient care.

Cepheid's oncology tests are an important addition to the company's product portfolio.

The company's focus on expanding its offerings in this area is a testament to its commitment to innovation and customer needs.

Intriguing read: Bcbs Breast Pump Texas

Cepheid has a significant presence in the global market, operating in 17 countries with production sites in the United States, Sweden, and India.

Cepheid's headquarters are located in two countries: Sunnyvale, California, serves as the United States headquarters, while Maurens-Scopont, France, is home to the European headquarters.

The company was listed on the Nasdaq in 2000, marking a significant milestone in its history.

Cepheid was acquired by Danaher Corporation in 2016, a Fortune 150 life science and technology innovator.

Being part of Danaher has allowed Cepheid to tap into the corporation's science and technology leadership, positioning its solutions at the forefront of the industry.

This partnership has enabled Cepheid to offer its customers unparalleled breadth and depth of expertise and solutions.

Together with Danaher's other businesses, Cepheid is able to unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

Curious to learn more? Check out: Danaher Subsidiaries

Cepheid, a molecular diagnostics company based in Sunnyvale, has received emergency approval from the FDA to use its test to detect SARS-CoV-2, the virus that causes COVID-19.

The test can deliver results within 45 minutes of taking the sample. This is significantly faster than other tests available, which can take hours or even days to produce results.

Cepheid's GeneXpert System is already used in many hospital labs across the country, allowing doctors to quickly determine if a patient tests positive for COVID-19. This system can provide a result in less than an hour.

The GeneXpert System can run tests 24/7, on-demand, which means each test can be run as it comes in, rather than requiring a group of samples to be collected before a test can be run.

Cepheid's system is designed to help hospitals manage the influx of patients by providing accurate and timely test results. This can help alleviate the pressure on healthcare facilities and allow them to properly allocate their resources.

Worth a look: List of Bank Stress Tests